• Key Findings of the NIAGARA and HIMALAYA Trials

  • 2024/11/08
  • 再生時間： 13 分
  • ポッドキャスト

Key Findings of the NIAGARA and HIMALAYA Trials

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • In this episode of the Pharmaceutical Executive podcast, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer, and much more.
    続きを読む 一部表示

あらすじ・解説

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer, and much more.
生物科学
続きを読む 一部表示

Key Findings of the NIAGARA and HIMALAYA Trialsに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。